IMP2

IMP2 is a non-specific identifier used in various contexts. In clinical trials, 'IMP2' frequently serves as a code name for Investigational Medicinal Product 2, referring to distinct drug formulations such as a lidocaine-23%-tetracaine-7% gel for wound debridement, a BioChaperone insulin lispro formulation for type 1 diabetes, or a lidocaine and sodium bicarbonate mixture for local anesthesia. Separately, 'IMP2' is also an abbreviation for Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), an RNA-binding protein that plays a significant role in tumorigenesis and metabolic disorders by regulating m6A-modified RNAs. IGF2BP2 (IMP2) is considered a promising therapeutic target for various cancers and metabolic diseases.

Other names

IGF2BP2IGF-2BP2IGF 2BP2Insulin-like growth factor 2 mRNA-binding protein 2